View all news

PBSV: Slow and steady wins the race.


By Beth Senko, CFA



Pharma-Bio Serv (OTC:PBSV) continued on a steady path in 3Q FY22. Higher sales in the US and Europe, offset continued softness in Puerto Rico. Gross margins improved vs. the year-earlier period.

As we’ve seen in the past few years, economic uncertainty continues to push out new project starts across the pharmaceutical industry. In July 2021, the US FDA resumed a normalized pace of cGMP, but a significant backlog remains. According to Fierce Pharma, at the end of 2021, the FDA reported it had completed 1,139 of its outstanding pharmaceutical and medical device inspections, roughly 35% of its backlog. In addition, the FDA reported that its backlog of NDA approval inspections rose to 52 in December, from 39 in May 2021. However, as of June 2022, the FDA reports that the NDA approval backlog is cleared; however, it is unclear whether meaningful backlog still exists for already approved drugs/manufacturing. As the FDA gets back to a normal pace of routine cGMP inspections, we expect PBSV’s new project pipeline to accelerate, particularly in Puerto Rico and the US.

For now, we are trimming our FY22 forecast and our valuation target slightly. Our FY22 revenue target is now $19.3 million, down from $20.8 million. We are lowering our FY22 EPS estimate from $0.08 to $0.05. For FY23, we are sticking with a conservative stance. Our new FY23 revenue target is $21.4 million, down from our earlier estimate of $22.7 million. Our FY23 EPS estimate is now $0.08, down from $0.10.

Recent results

In 3Q FY22, Pharma-Bio Serv’s revenues were $4.8 million, down $0.2 million from the year earlier period. While weakness continues in the Puerto Rico consulting market, US business is running at nearly double the rate in FY21. In 3Q FY22, sales in the US rose, ~78% YoY to $1.1 million; sales in Europe climbed 12% YoY to $0.65 million in the quarter.

Gross profit margins in the quarter improved 230 bps YoY and 300 bps sequentially, due largely to higher margined projects in both Puerto Rico and Europe. Long-term, we model gross margins in the 30-31% range. Project staffing is the Company’s primary expense and is largely variable, so margin expansion will come primarily through leveraging SG&A. Net income for the quarter was $0.3 million, up from $0.24 million in 2Q FY22. However net income declined ~$2.0 million, on a YoY basis, as 3Q FY21 net income included PPP loan forgiveness.

At July 31, the Company had $14.2 million in cash on its balance sheet. The Company continues its share repurchase program, of which 1.55 million shares are still authorized for repurchase. With the shares trading at book value, and modest capital expense and working investment needs, we view this as a reasonable action.

The Company’s has emphasized organic growth in Puerto Rico and increasingly in other geographies. In addition, the Company looks to provide GMP services outside its core pharmaceutical client base, such as food, and cosmetic manufacturers. Any additional investments the Company makes in its business and the rate of its expansion will factor significantly in both our forecasts and financial valuation.

Our target valuation is unchanged at $1.77, driven primarily improving gross margins (vs. FY21) and slower than expected growth in SG&A spend.

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. 

DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.

Multimedia Files:

Categories: Press Releases
View all news